The Comparison Effect of Ciprofloxacin and Cotrimoxazole in Infection Prophylaxis during Chemotherapy Treatment of Multiple Myeloma Patients
Introduction: Infections are the main cause of mortality in half of the patients suffering multiple myeloma and disrupt the treatment process. Administration of the best prophylactic antibiotic with a minimum of complications is of prime importance. Aim of this study was to compare two antibiotics of Co-trimoxazole and Ciprofloxacin with different functional mechanisms.
Material and Method: 72 new patients suffering from multiple myeloma were admitted in this clinical trial study. The patients were divided into two equal groups by simple randomization. The first group received 500 mg ciprofloxacin capsules once daily, and the second group received co-trimoxazole tablets at a dose of 160/400 daily for 4 weeks. Occurrence of various types of infections were followed and compared by clinical and laboratory methods for a period of 6 months.
Results: Sex ratio, mean age, and the type of regimen prescribed to the patients were not different between two groups (p ≥ 0.05). The occurrence of infection in the ciprofloxacin group was 16.7% (6 cases) and 38.9% (14 cases) in the cotrimoxazole group during the 6 months (p ≤ 0.05). The most common type of infection in both groups was pneumonia. There was no significant difference in the occurrence of infection according to the type of regimen prescribed to the patients (p ≥ 0.05). No serious complication resulting in discontinuation of treatment was reported in the two groups. The bacterial resistance to ciprofloxacin was less than co-trimoxazole.
Conclusion: It was concluded that ciprofloxacin with less resistance can be routinely used in the prevention of various infections during the chemotherapy. In multiple myeloma, infection control as well as recognition of risk factors and phase of the disease has the main role in treatment.